MSAM
HEPA

Moloney Securities Asset Management’s Hepion Pharmaceuticals HEPA Stock Holding History

Moloney Securities Asset Management’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-27
Closed -$54K – 448
2021
Q2 		$54K Buy
+27
New +$49.4K 0.01% 417

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AMC
Asset Management Corp Northbrook, Illinois $128M AUM 6.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Moloney Securities Asset Management's HEPA Position: Q3 2021 in Review

Moloney Securities Asset Management sold out of Hepion Pharmaceuticals (HEPA) in Q3 2021, closing a stake of 27 shares — an estimated $54K sold.

Moloney Securities Asset Management first reported a position in HEPA in Q2 2021 and held it in 1 quarter. The position peaked at $54K in Q2 2021. 37 funds tracked by Wall St. Rank hold HEPA as of Q3 2021.

  • Moloney Securities Asset Management reported no remaining Hepion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Moloney Securities Asset Management sold 27 Hepion Pharmaceuticals shares in Q3 2021, an estimated $54K.
  • Moloney Securities Asset Management first reported a position in Hepion Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Moloney Securities Asset Management's Hepion Pharmaceuticals position peaked at $54K in Q2 2021.
  • 37 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q3 2021.

Based on Moloney Securities Asset Management's 13F filing for Q3 2021, filed 27 Oct 2021.